Codexis, Inc. (CDXS)
CDXS Stock Price Chart
Explore Codexis, Inc. interactive price chart. Choose custom timeframes to analyze CDXS price movements and trends.
CDXS Company Profile
Discover essential business fundamentals and corporate details for Codexis, Inc. (CDXS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
22 Apr 2010
Employees
188.00
Website
https://www.codexis.comCEO
Stephen George Dilly MBBS,
Description
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
CDXS Financial Timeline
Browse a chronological timeline of Codexis, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 30 Oct 2025
EPS estimate is -$0.15, while revenue estimate is $18.52M.
Earnings released on 13 Aug 2025
EPS came in at -$0.16 surpassing the estimated -$0.17 by +5.88%, while revenue for the quarter reached $15.33M , missing expectations by -21.31%.
Earnings released on 14 May 2025
EPS came in at -$0.25 falling short of the estimated -$0.20 by -25.00%, while revenue for the quarter reached $7.54M , missing expectations by -21.94%.
Earnings released on 27 Feb 2025
EPS came in at -$0.13 falling short of the estimated -$0.04 by -225.00%, while revenue for the quarter reached $21.46M , missing expectations by -21.71%.
Earnings released on 31 Oct 2024
EPS came in at -$0.29 falling short of the estimated -$0.25 by -16.00%, while revenue for the quarter reached $12.83M , missing expectations by -53.18%.
Earnings released on 8 Aug 2024
EPS came in at -$0.32 falling short of the estimated -$0.26 by -23.08%, while revenue for the quarter reached $7.98M , beating expectations by +2.03%.
Earnings released on 2 May 2024
EPS came in at -$0.16 surpassing the estimated -$0.17 by +5.88%, while revenue for the quarter reached $17.07M , beating expectations by +24.99%.
Earnings released on 28 Feb 2024
EPS came in at $0.02 surpassing the estimated -$0.16 by +112.50%, while revenue for the quarter reached $26.56M , beating expectations by +33.47%.
Earnings released on 2 Nov 2023
EPS came in at -$0.26 surpassing the estimated -$0.32 by +18.75%, while revenue for the quarter reached $9.28M , missing expectations by -7.51%.
Earnings released on 3 Aug 2023
EPS came in at -$0.17 surpassing the estimated -$0.21 by +19.05%, while revenue for the quarter reached $21.32M , beating expectations by +1.15%.
Earnings released on 4 May 2023
EPS came in at -$0.34 falling short of the estimated -$0.29 by -17.24%, while revenue for the quarter reached $12.98M , missing expectations by -7.86%.
Earnings released on 23 Feb 2023
EPS came in at -$0.19 surpassing the estimated -$0.23 by +17.39%, while revenue for the quarter reached $30.38M , beating expectations by +4.99%.
Earnings released on 3 Nov 2022
EPS came in at -$0.15 surpassing the estimated -$0.18 by +16.67%, while revenue for the quarter reached $34.47M , beating expectations by +11.41%.
Earnings released on 4 Aug 2022
EPS came in at -$0.04 surpassing the estimated -$0.14 by +71.43%, while revenue for the quarter reached $38.41M , beating expectations by +0.79%.
Earnings released on 5 May 2022
EPS came in at -$0.13 surpassing the estimated -$0.18 by +27.78%, while revenue for the quarter reached $35.34M , beating expectations by +23.62%.
Earnings released on 24 Feb 2022
EPS came in at -$0.16 surpassing the estimated -$0.18 by +11.11%, while revenue for the quarter reached $24.50M , beating expectations by +5.59%.
Earnings released on 4 Nov 2021
EPS came in at $0.03 surpassing the estimated -$0.09 by +133.33%, while revenue for the quarter reached $36.77M , beating expectations by +29.01%.
Earnings released on 5 Aug 2021
EPS came in at -$0.07 surpassing the estimated -$0.17 by +58.82%, while revenue for the quarter reached $25.45M , beating expectations by +38.78%.
Earnings released on 6 May 2021
EPS came in at -$0.14 surpassing the estimated -$0.20 by +30.00%, while revenue for the quarter reached $18.03M , missing expectations by -23.08%.
Earnings released on 25 Feb 2021
EPS came in at -$0.06 surpassing the estimated -$0.13 by +53.85%, while revenue for the quarter reached $21.03M , missing expectations by -25.92%.
Earnings released on 5 Nov 2020
EPS came in at -$0.10 surpassing the estimated -$0.16 by +37.50%, while revenue for the quarter reached $18.39M , missing expectations by -9.09%.
CDXS Stock Performance
Access detailed CDXS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.